Jeffrey Borgia to Biomarkers
This is a "connection" page, showing publications Jeffrey Borgia has written about Biomarkers.
Connection Strength
1.296
-
The serum-based VeriStrat? test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. 2018 03 20; 18(1):310.
Score: 0.486
-
The MindMoves Trial: Cross-Sectional Analyses of Baseline Vascular Risk and Cognition in Older Women with Cardiovascular Disease. J Alzheimers Dis. 2024; 100(4):1407-1416.
Score: 0.181
-
Development of exploratory algorithms to aid in risk of malignancy prediction of indeterminate pulmonary nodules. Clin Chim Acta. 2022 Oct 01; 535:197-202.
Score: 0.166
-
Reply. Ann Thorac Surg. 2018 07; 106(1):316-317.
Score: 0.120
-
Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters. Ann Thorac Surg. 2017 Nov; 104(5):1637-1643.
Score: 0.118
-
Development of a bead-based immunoassay to routinely measure vimentin autoantibodies in the clinical setting. J Immunol Methods. 2014 May; 407:9-14.
Score: 0.092
-
Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer. Ann Thorac Surg. 2011 Nov; 92(5):1805-11; discussion 1811.
Score: 0.078
-
Plasma small ncRNA pair panels as novel biomarkers for early-stage lung adenocarcinoma screening. BMC Genomics. 2018 Jul 20; 19(1):545.
Score: 0.031
-
Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia. Leuk Lymphoma. 2015; 56(11):3135-42.
Score: 0.025